Comorbidity and competing risks for mortality in men with prostate cancer.
about
Predicting mortality from change-over-time in the Charlson Comorbidity Index: A retrospective cohort study in a data-intensive UK health systemCalprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study.Are HIV-infected men vulnerable to prostate cancer treatment disparities?Predictors of competing mortality to invasive breast cancer incidence in the Canadian National Breast Screening study.Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancerEvaluation and Management of the Geriatric Urologic Oncology Patient.Multimorbidity: an issue of growing importance for oncologistsAdjusted Age-Adjusted Charlson Comorbidity Index Score as a Risk Measure of Perioperative Mortality before Cancer Surgery.Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based modelCHADS2 scores as a predictor of ischemic stroke after radical prostatectomy.Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel.Overdiagnosis of prostate cancer.Body mass index and prostate cancer severity: do obese men harbor more aggressive disease on prostate biopsy?Impact of comorbidity in elderly prostate cancer patients treated with brachytherapy.Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancerEvaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogramComorbidity and survival of Danish prostate cancer patients from 2000-2011: a population-based cohort study.Consideration of comorbidity in risk stratification prior to prostate biopsy.Comorbidity and survival of patients selected for radical prostatectomy at an age of 75 years or older.Charlson comorbidity index is an important prognostic factor for long-term survival outcomes in Korean men with prostate cancer after radical prostatectomy.Risk-based prostate cancer screening.Risk-based prostate cancer screening: who and how?Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer?Exercise does not counteract the effects of a "westernized" diet on prostate cancer xenografts.Digoxin and 30-Day All-Cause Readmission in Long-Term Care Residents Hospitalized for Heart Failure.Age-adjusted Charlson comorbidity index is a significant prognostic factor for long-term survival of patients with high-risk prostate cancer after radical prostatectomy: a Bayesian model averaging approach.Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy.Patient comorbidity is associated with conservative treatment of localized prostate cancer.Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy.Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma.Racial parity in tumor burden, treatment choice and survival outcomes in men with prostate cancer in the VA healthcare system.Reply to Charlson score and competing mortality.Matching tumor risk with aggressiveness of treatment in men with multiple comorbidities and early-stage prostate cancer.Comparative effectiveness of aggressive versus nonaggressive treatment among men with early-stage prostate cancer and differing comorbid disease burdens at diagnosis.Does Certificate of Need Minimize Intensity Modulated Radiation Therapy Use in Patients with Low Risk Prostate Cancer?Incidence of invasive breast cancer in the presence of competing mortality: the Canadian National Breast Screening Study.Effect of Comorbidity on Prostate Cancer-Specific Mortality: A Prospective Observational Study.Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance.Current impact of age and comorbidity assessment on prostate cancer treatment choice and over/undertreatment risk.Impact of Charlson comorbidity index varies by age in patients with prostate cancer treated by radical prostatectomy: a competing risk regression analysis.
P2860
Q31139385-7A9A68E8-7E54-4A08-B6C9-20E6770EA9BCQ34110399-120B04E3-A3A7-47AD-9915-A1DA378427DDQ34288005-741003A5-D2CF-4ECB-B8C7-EDFFD794B81AQ34343656-62589DA8-CC8E-4759-BDD0-9AADE194DCB5Q34550547-D1BF03BE-6B19-4B2A-969F-355F1812EB8FQ35063815-6E9ED774-573E-4BF5-8744-10C45B5F267EQ35559778-E283E727-827C-421F-8B4B-A86756FD0D2FQ35915451-504728BB-18A1-47D7-954F-99D17DE2415DQ36319704-1F54372C-5C04-42E0-8B7E-B64497643FFDQ36451523-F2F8535C-A38A-41F4-B427-0C504D668AE1Q36490409-4B3ABFD5-18C2-4FFF-BDB4-2FE36326861AQ36520508-E25902FD-C792-47F6-8AD5-42F24920D7E2Q36791463-324040CD-C1DD-481B-B7EB-77C0F8D32E8FQ36967491-A41141C1-3E79-4F76-86D1-8FA98226DBD4Q37140722-5EFCB3AA-7A64-4B3C-AD67-7B94EE193799Q37274238-60D505A1-A942-439B-A1AA-46562BD396E7Q37288158-EDDA1697-A51E-4047-B516-0DD84D8218AAQ37415134-7CD1C55C-EE3F-4BCB-9B7B-23F8054A1F91Q37437038-FEA7A527-CCC8-432A-909C-0562FBBB507AQ37606713-7A011F35-C038-41D0-BF19-F70100846A67Q37963657-2719870A-9DE4-4D68-9176-FD7211633D1FQ38093463-E1D99600-4ECB-4A1F-8926-578CEDA61023Q38151298-3E3050C7-28F0-48F4-AB6D-7F4096111B35Q39158438-4E9580EF-DD5F-4983-BC03-7501652D70EFQ40202565-03421AEC-09F4-477F-A055-BFDC61406AF4Q40218603-AFA68F31-346B-4189-862A-FEBB7009A3CBQ40897976-24DC31E1-1BF6-4656-B594-CA7196679123Q41028107-60016B96-89F3-4EA9-A033-CCB9337F12FEQ42910816-212CE331-B93B-48EA-8D4D-055EA9D5FECFQ43117102-73A431D6-E54B-4C53-B588-2AFA3779FD8BQ45996743-D7553C54-50C4-4B03-8DB8-F9B18C2AC7BBQ46009818-73856819-3721-497D-BB7A-16CDA8A2FB7DQ46066104-62B2CB7B-86D9-4392-94BF-8B54B293DDD8Q46763090-48C825DC-78B3-4162-9AA0-FA803DDE827FQ47103552-F7F12F51-66E6-4ED7-B0F3-29F3379F7ED8Q47634844-29E6907C-88DB-45B3-840D-EF457912F22DQ47773046-B83E1BB7-F27C-4A79-BCB0-BF8CB8DD184BQ51778109-30200309-4575-4F3B-B650-7D853FB62692Q53063187-8D2C2958-232C-4D07-A9A5-5D45C5A689E3Q54717140-51B8EC2B-7658-496A-8206-C510B0A91EA3
P2860
Comorbidity and competing risks for mortality in men with prostate cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Comorbidity and competing risks for mortality in men with prostate cancer.
@en
Comorbidity and competing risks for mortality in men with prostate cancer.
@nl
type
label
Comorbidity and competing risks for mortality in men with prostate cancer.
@en
Comorbidity and competing risks for mortality in men with prostate cancer.
@nl
prefLabel
Comorbidity and competing risks for mortality in men with prostate cancer.
@en
Comorbidity and competing risks for mortality in men with prostate cancer.
@nl
P2093
P2860
P356
P1433
P1476
Comorbidity and competing risks for mortality in men with prostate cancer
@en
P2093
Atreya Dash
Jessica Labo
Karim Chamie
Lorna Kwan
Mark S Litwin
Timothy J Daskivich
P2860
P304
P356
10.1002/CNCR.26104
P407
P577
2011-04-08T00:00:00Z